TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia

Haematologica. 2019 Sep;104(9):e402-e405. doi: 10.3324/haematol.2018.205849. Epub 2019 Jul 9.

Authors

Affiliations

¹ Pediatric Hematology and Oncology, Hannover Medical School, Hannover.
² Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel.
³ Department of Pathology, Ruhr-University Bochum, Bochum, Germany.
⁴ Pediatric Hematology and Oncology, Hannover Medical School, Hannover [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Child
Child, Preschool
Core Binding Factor Alpha 2 Subunit / genetics*
ETS Translocation Variant 6 Protein
Female
Follow-Up Studies
Genetic Predisposition to Disease
Genotype
Germ-Line Mutation*
Humans
Infant
Male
Neoplasms, Second Primary / genetics*
Pilot Projects
Polymorphism, Single Nucleotide
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Proto-Oncogene Proteins c-ets / genetics*
Repressor Proteins / genetics*
Tumor Suppressor Protein p53 / genetics*

Substances

Core Binding Factor Alpha 2 Subunit
Proto-Oncogene Proteins c-ets
RUNX1 protein, human
Repressor Proteins
TP53 protein, human
Tumor Suppressor Protein p53